KIMIA BIOSCIENCES LIMITED
Latest filings
- Routine dematerialization compliance certificate for Q2 FY27 · Compliance
- Board changes approved at 33rd AGM, independent directors appointed · Management Changes
- AGM 2026: All 10 resolutions passed; borrowing and investment limits raised · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs) and finished pharmaceutical products, operating in the small-cap pharmaceutical space on BSE. The filing pack identifies Luliconazole — an antifungal API — as a specific product, with the company having secured a 20-year Indian patent (No. 579384) for an improved manufacturing process, granted January 29, 2026. FY26 revenue from operations stood at Rs 114.88 crore, down 3.4% year-on-year, with a single reported segment ('Revenue from Operations') making up 100% of segment revenue in the most recent disclosed period. Net profit for FY26 was Rs 7.43 crore, with the company spending Rs 65.66 crore on materials (57.2% of revenue), Rs 12.62 crore on employees (11.0%), and Rs 8.16 crore on capex (7.1%). R&D spend was significant enough to be reclassified from expense to intangible assets where recognition criteria were met, indicating active development work. Working capital facilities of Rs 29.60 crore are sanctioned from Kotak Mahindra Bank, of which Rs 22.71 crore was utilised as of March 31, 2026.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from KIMIA BIOSCIENCES LIMITED's filed financials and exchange disclosures
What does KIMIA BIOSCIENCES LIMITED do?
KIMIA BIOSCIENCES LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.
Is KIMIA BIOSCIENCES LIMITED profitable?
Yes. Over the trailing twelve months KIMIA BIOSCIENCES LIMITED reported a net profit of ₹7.43 Cr on revenue of ₹115 Cr.
Does KIMIA BIOSCIENCES LIMITED pay a dividend?
Not in the latest reported year — KIMIA BIOSCIENCES LIMITED's dividend payout for FY26 was nil.
Is KIMIA BIOSCIENCES LIMITED debt-free?
No. It reported borrowings of ₹35 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹34 Cr after cash. Debt stands at 1.95× equity. That is higher than 98% of its 166 Pharmaceuticals peers.
Is KIMIA BIOSCIENCES LIMITED expensive compared with its peers?
On trailing P/E, KIMIA BIOSCIENCES LIMITED ranks 45 of 158 in Pharmaceuticals — cheaper than 72% of them, against an industry median of 30.2×. This is a position, not a valuation judgement.
How much does the KIMIA BIOSCIENCES LIMITED share price move in a day?
On a typical session KIMIA BIOSCIENCES LIMITED moves 2.05% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track KIMIA BIOSCIENCES LIMITED's announcements?
Every NSE and BSE filing by KIMIA BIOSCIENCES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.